OBJECTIVES: An expert panel of Canadian dermatologists was assembled to develop consensus statements regarding the current landscape of topical therapies for plaque psoriasis and the place in therapy of the recently approved fixed-dose combination halobetasol propionate (HP) / tazarotene (TAZ) lotion (HP/TAZ) in the treatment algorithm for plaque psoriasis.

METHODS: A modified nominal group technique, which combined both independent and group input from the expert panel, was used to develop the consensus statements. The expert panel completed surveys to elicit their independent views on the current landscape of topical therapies for plaque psoriasis in Canada. The first expert panel session was held to discuss the existing body of literature and develop draft consensus statements about topical therapies and the place in therapy of HP/TAZ. Independent feedback on the draft consensus statements was solicited from expert panel members prior to another expert panel session where the amended consensus statements were further discussed, edited and, finally, voted on.

RESULTS: The expert panel reached consensus on 20 statements. Studies have shown that HP/TAZ is effective and safe in treating moderate-to-severe plaque psoriasis as a first-line option. Due to its cosmetically acceptable vehicle and once-daily administration, HP/TAZ has favourable patient acceptance and treatment adherence.

CONCLUSIONS: Expert panel members agreed, based on the existing body of literature, that there is a place in therapy for HP/TAZ to address several current unmet treatment needs of patients with plaque psoriasis.